Raymond James & Associates Adma Biologics, Inc. Transaction History

Raymond James & Associates

$150 Billion
Q2 2024

A detailed history of Raymond James & Associates transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 278,227 shares of ADMA stock, worth $5.44 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

278,227

Previous 284,193 2.1%

Holding current value

$5.44 Million

Previous $1.88 Million 65.87%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	SELL	$5.98 - $11.18 $35,676 - $66,699	-5,966 Reduced 2.1%	278,227 $3.11 Million
Q1 2024 Apr 22, 2024	BUY	$4.4 - $6.74 $153,546 - $235,205	34,897 Added 14.0%	284,193 $1.88 Million
Q4 2023 Jan 16, 2024	BUY	$3.08 - $4.52 $17,423 - $25,569	5,657 Added 2.32%	249,296 $1.13 Million
Q3 2023 Oct 24, 2023	BUY	$3.47 - $4.61 $34,762 - $46,182	10,018 Added 4.29%	243,639 $872,000
Q2 2023 Jul 25, 2023	SELL	$3.12 - $4.22 $25,755 - $34,836	-8,255 Reduced 3.41%	233,621 $862,000
Q1 2023 Apr 14, 2023	BUY	$3.01 - $3.87 $15,119 - $19,439	5,023 Added 2.12%	241,876 $800,000
Q4 2022 Feb 08, 2023	SELL	$2.47 - $3.88 $38,828 - $60,993	-15,720 Reduced 6.22%	236,853 $918,000
Q3 2022 Oct 25, 2022	SELL	$2.03 - $2.86 $32,648 - $45,997	-16,083 Reduced 5.99%	252,573 $614,000
Q2 2022 Aug 12, 2022	BUY	$1.43 - $2.2 $98,200 - $151,078	68,672 Added 34.34%	268,656 $532,000
Q1 2022 May 11, 2022	BUY	$1.28 - $1.83 $49,555 - $70,848	38,715 Added 24.01%	199,984 $366,000
Q4 2021 Feb 08, 2022	BUY	$1.09 - $1.66 $9,903 - $15,082	9,086 Added 5.97%	161,269 $227,000
Q3 2021 Nov 02, 2021	BUY	$1.13 - $1.65 $32,802 - $47,897	29,029 Added 23.57%	152,183 $172,000
Q2 2021 Aug 11, 2021	SELL	$1.51 - $2.07 $85,068 - $116,617	-56,337 Reduced 31.39%	123,154 $197,000
Q1 2021 May 14, 2021	BUY	$1.67 - $2.95 $72,147 - $127,445	43,202 Added 31.7%	179,491 $316,000
Q4 2020 Feb 12, 2021	SELL	$1.8 - $2.56 $81,651 - $116,126	-45,362 Reduced 24.97%	136,289 $266,000
Q3 2020 Nov 04, 2020	SELL	$2.04 - $3.74 $156,698 - $287,280	-76,813 Reduced 29.72%	181,651 $434,000
Q2 2020 Jul 28, 2020	BUY	$2.42 - $3.29 $83,911 - $114,077	34,674 Added 15.49%	258,464 $757,000
Q1 2020 Apr 21, 2020	BUY	$1.5 - $4.59 $155,317 - $475,271	103,545 Added 86.11%	223,790 $645,000
Q4 2019 Feb 12, 2020	BUY	$3.89 - $5.15 $273,031 - $361,468	70,188 Added 140.22%	120,245 $481,000
Q3 2019 Nov 07, 2019	BUY	$3.19 - $5.39 $2,571 - $4,344	806 Added 1.64%	50,057 $223,000
Q2 2019 Aug 06, 2019	BUY	$3.52 - $5.24 $121,549 - $180,942	34,531 Added 234.59%	49,251 $191,000
Q1 2019 May 06, 2019	SELL	$2.61 - $4.35 $31,714 - $52,856	-12,151 Reduced 45.22%	14,720 $56,000
Q4 2018 Feb 11, 2019	BUY	$2.17 - $6.12 $23,023 - $64,933	10,610 Added 65.25%	26,871 $64,000
Q3 2018 Nov 14, 2018	SELL	$4.39 - $6.85 $22,209 - $34,654	-5,059 Reduced 23.73%	16,261 $101,000
Q2 2018 Aug 14, 2018	BUY	$4.39 - $5.44 $93,594 - $115,980	21,320 New	21,320 $96,000

Others Institutions Holding ADMA

# of Institutions

265

Shares Held

178M

Call Options Held

535K

Put Options Held

21.2K

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.84B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Adma Biologics, Inc. Transaction History